Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Insights into the Phase II TIDAL study

Tycel Phillips, MD, City of Hope, Duarte, CA, shares some insights into the Phase II TIDAL study (NCT03768505), which is evaluating the safety and efficacy of zandelisib in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL) who have failed at least two prior lines of therapy. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.